respons
cox
letter
contain
number
fals
assumpt
error
mislead
assert
misquot
cox
assert
annual
person
fewer
unit
state
experi
advers
effect
fluoroquinolon
use
poultri
reduc
referenc
risk
person
acquir
campylobact
infect
poultri
unrealist
low
estim
given
referenc
citat
estim
risk
also
much
lower
refer
cox
quot
poultri
common
caus
sporad
case
campylobacteriosi
unit
state
econom
research
servic
us
depart
agricultur
cox
know
assert
poultri
make
littl
contribut
human
campylobact
infect
extens
examin
found
wrong
inde
entir
section
recent
us
food
drug
administr
fda
determin
written
unreli
cox
testimoni
assert
find
made
fda
commission
administr
law
judg
cox
also
misquot
busbi
et
al
assert
person
campylobact
infect
benefit
antimicrobi
drug
busbi
articl
state
person
campylobact
infect
need
hospit
mani
would
benefit
antimicrobi
drug
therapi
cox
thu
made
mislead
attribut
someth
previous
found
busbi
et
al
estim
person
unit
state
acquir
campylobact
infect
food
sourc
even
proport
benefit
receiv
antimicrobi
drug
low
translat
person
infect
caus
fluoroquinoloneresist
campylobact
spp
person
would
potenti
therapi
outcom
compromis
rather
person
cox
would
us
believ
realist
figur
person
estim
previous
risk
advers
outcom
person
everi
million
chicken
treat
fluoroquinolon
cox
assumpt
calcul
thu
seem
flaw
unrealist
editor
defend
avian
influenza
viru
possibl
adopt
treatment
develop
biodefens
overlook
biodefens
medicin
primarili
concern
respiratori
infect
bioweapon
deadliest
form
dispers
bacillu
anthraci
yersinia
pesti
caus
anthrax
plagu
highli
contagi
virus
like
smallpox
ebola
marburg
aerosol
nation
institut
health
depart
defens
fund
develop
novel
biodefens
medic
design
stimul
innat
mucos
immun
use
interferon
ifn
interferon
induc
suggest
studi
begin
immedi
explor
potenti
ifn
prevent
infect
reduc
death
caus
avian
influenza
virus
anim
model
human
modul
innat
mucos
immun
promis
rapidact
broadspectrum
approach
combat
bioterror
innat
immun
initi
respons
pathogen
potenti
capabl
erad
infect
even
innat
immun
respons
elimin
viru
may
substanti
reduc
viral
load
reduc
patholog
facilit
clear
viru
adapt
immun
respons
slow
spread
infect
biodefens
medic
ifn
ifninduc
develop
aerosol
deliveri
lung
convent
ifn
administr
inject
often
result
low
concentr
target
site
high
concentr
circul
may
caus
seriou
side
effect
aerosol
deliveri
minim
side
effect
produc
rapid
clinic
respons
inhal
ifn
proven
well
toler
benefici
rhinoviru
infect
pulmonari
tuberculosi
medic
preclin
stage
develop
ampligen
aldara
approv
genit
wart
actin
keratos
basal
cell
carcinoma
other
drug
test
aerosol
deliveri
modul
mucos
immun
respiratori
tract
could
expediti
test
inhal
intranas
administr
model
mice
ferret
pig
monkey
work
bind
receptor
activ
downstream
antivir
pathway
involv
dsrnadepend
protein
kinas
pkr
oligoadenyl
synthetasernas
l
mxa
protein
dsrna
ssrna
cpg
oligonucleotid
ligand
tolllik
receptor
tlr
modul
antivir
immun
tlr
signal
pathway
ifn
induct
cellular
level
insid
lung
drug
enhanc
phagocytot
cytolyt
activ
alveolar
macrophag
infect
establish
resist
antivir
effect
ifn
tumor
necrosi
resist
associ
nonstructur
gene
may
mechan
extraordinari
virul
therefor
prophylact
use
ifn
ifninduc
critic
combat
may
also
effect
administ
immedi
infect
ifn
resist
also
exist
viral
infect
instanc
poxvirus
includ
vaccinia
viru
encod
protein
interfer
rnasel
pkr
pathway
solubl
ifn
receptor
interfer
ifninduc
antivir
pathway
nevertheless
least
anim
model
preinfect
administr
exogen
ifn
reduc
death
poxviru
viral
load
mice
intranas
administr
prevent
lethal
vaccinia
infect
ifn
induc
poli
iclc
protect
mice
infect
influenza
viru
henc
suggest
prophylaxi
ifnstimul
innat
mucos
immun
promis
therapi
worth
immedi
investig
anim
model
second
mechan
propos
explain
virul
also
ifn
relat
cytokin
storm
shown
elev
level
proinflammatori
cytokin
includ
ifn
found
patient
die
infect
cytokin
storm
result
autoimmun
reaction
tissu
damag
septic
shock
high
ifn
dose
long
period
may
exacerb
autoimmun
howev
despit
similar
cytokin
storm
sever
acut
respiratori
syndrom
patient
respond
well
ifn
therapi
optim
formul
regimen
ifn
administr
could
crucial
effect
prophylaxi
interest
safeti
propos
initi
prophylaxi
studi
use
rel
low
ifn
dose
short
period
week
unlik
drug
effect
protect
drug
effect
might
work
everyon
genet
polymorph
influenc
ifn
respons
howev
fda
approv
even
one
might
save
mani
live
